Nutriband Inc. Announces 25% Preferred Stock Dividend Tied to AVERSA Fentanyl FDA Approval
Nutriband Inc. (NASDAQ: NTRB) has declared a 25% preferred stock dividend, contingent on FDA approval of its AVERSA Fentanyl product, highlighting its strategy to enhance shareholder value during the product's commercialization phase.
Nutriband Inc. (NASDAQ: NTRB) has taken a significant step towards rewarding its shareholders by announcing a 25% preferred stock dividend. This dividend will grant one preferred share for every four common shares held as of July 25, 2025, with the distribution scheduled for August 5. The unique aspect of this dividend is its linkage to the FDA approval of the company's AVERSA Fentanyl product, a move that underscores Nutriband's confidence in its product pipeline and its commitment to shareholder value.
The preferred shares are designed to convert into common shares upon the FDA's approval of AVERSA Fentanyl, a product that incorporates Nutriband's proprietary AVERSA abuse-deterrent technology. This technology aims to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, marking a significant advancement in transdermal pharmaceutical products. Should the conversion not occur, these preferred shares will then be eligible for annual cash dividends, subject to the Board's discretion and the company's profitability.
CEO Gareth Sheridan emphasized that this initiative reflects the company's dedication to enhancing shareholder value as it progresses towards the commercialization of AVERSA Fentanyl. This announcement not only highlights Nutriband's strategic focus on developing innovative pharmaceutical solutions but also its proactive approach to engaging with its investor community. For more details on this development, visit https://ibn.fm/4dkCf.